Literature DB >> 24170145

Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes.

Philipp Schuetz1, Beat Mueller.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24170145     DOI： 10.1007/s00134-013-3139-x

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  3 in total

1.  De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock.

Authors:  J Garnacho-Montero; A Gutiérrez-Pizarraya; A Escoresca-Ortega; Y Corcia-Palomo; Esperanza Fernández-Delgado; I Herrera-Melero; C Ortiz-Leyba; J A Márquez-Vácaro
Journal:  Intensive Care Med       Date:  2013-09-12       Impact factor: 17.440

Review 2.  Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.

Authors:  Philipp Schuetz; Beat Müller; Mirjam Christ-Crain; Daiana Stolz; Michael Tamm; Lila Bouadma; Charles E Luyt; Michel Wolff; Jean Chastre; Florence Tubach; Kristina B Kristoffersen; Olaf Burkhardt; Tobias Welte; Stefan Schroeder; Vandack Nobre; Long Wei; Neera Bhatnagar; Heiner C Bucher; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

3.  Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections.

Authors:  Philipp Schuetz; Matthias Briel; Beat Mueller
Journal:  JAMA       Date:  2013-02-20       Impact factor: 56.272
  3 in total
  7 in total

1.  What can be expected from antimicrobial de-escalation in the critically ill?

Authors:  Marin H Kollef
Journal:  Intensive Care Med       Date:  2013-11-19       Impact factor: 17.440

2.  Determining the Clinical Utility of an Absolute Procalcitonin Value for Predicting a Positive Culture Result.

Authors:  Erica M Caffarini; Joshua DeMott; Gourang Patel; Ishaq Lat
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 3.  Role of procalcitonin use in the management of sepsis.

Authors:  Claudia Gregoriano; Eva Heilmann; Alexandra Molitor; Philipp Schuetz
Journal:  J Thorac Dis       Date:  2020-02       Impact factor: 2.895

4.  Need for a biomarker to de-escalate antimicrobial empirical therapy.

Authors:  José Garnacho-Montero; Antonio Gutiérrez-Pizarraya; Ana Escoresca-Ortega
Journal:  Intensive Care Med       Date:  2013-12-03       Impact factor: 17.440

Review 5.  Systematic review regarding metabolic profiling for improved pathophysiological understanding of disease and outcome prediction in respiratory infections.

Authors:  Manuela Nickler; Manuel Ottiger; Christian Steuer; Andreas Huber; Janet Byron Anderson; Beat Müller; Philipp Schuetz
Journal:  Respir Res       Date:  2015-10-15

6.  Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.

Authors:  Philipp Schuetz; Robert Birkhahn; Robert Sherwin; Alan E Jones; Adam Singer; Jeffrey A Kline; Michael S Runyon; Wesley H Self; D Mark Courtney; Richard M Nowak; David F Gaieski; Stefan Ebmeyer; Sascha Johannes; Jan C Wiemer; Andrej Schwabe; Nathan I Shapiro
Journal:  Crit Care Med       Date:  2017-05       Impact factor: 7.598

7.  Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials.

Authors:  Yannick Wirz; Marc A Meier; Lila Bouadma; Charles E Luyt; Michel Wolff; Jean Chastre; Florence Tubach; Stefan Schroeder; Vandack Nobre; Djillali Annane; Konrad Reinhart; Pierre Damas; Maarten Nijsten; Arezoo Shajiei; Dylan W deLange; Rodrigo O Deliberato; Carolina F Oliveira; Yahya Shehabi; Jos A H van Oers; Albertus Beishuizen; Armand R J Girbes; Evelien de Jong; Beat Mueller; Philipp Schuetz
Journal:  Crit Care       Date:  2018-08-15       Impact factor: 9.097
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.